Digital healthcare has expanded as technology companies explore ways to provide medical services through online platforms. Eucalyptus, co-founded by Tim Doyle and three other founders, developed a model combining telehealth consultations, prescriptions and medication delivery across several healthcare categories.

The company’s development reflects both the opportunities and regulatory considerations involved in building businesses in healthcare technology.

Building a digital healthcare company

Eucalyptus was founded in 2019 by Tim Doyle, Charlie Gearside, Benny Kleist and Alexey Mitko.

The company developed digital healthcare services through separate brands focused on specific health areas, including men’s health, women’s health, dermatology and reproductive health.

Doyle became chief executive and a public representative of the company, while the Business was built through the combined efforts of the founding team.

Developing an online healthcare model

Eucalyptus focused on providing healthcare services through digital channels.

The company’s model involved online consultations, prescription services where appropriate and medication delivery.

Digital healthcare platforms aim to reduce some barriers associated with traditional healthcare access, including appointment availability, travel requirements and scheduling challenges.

However, healthcare services delivered online must also operate within regulatory requirements and clinical standards.

Expansion and acquisition

Eucalyptus expanded beyond Australia into markets including the United Kingdom, Germany, Japan and Canada.

The company raised Investment as it developed its platform and expanded operations.

In 2026, Eucalyptus agreed to be acquired by United States-based digital healthcare company Hims and Hers Health, with the transaction completing later that year.

The Acquisition followed several years of development after the company’s founding in 2019.

Regulatory discussions around telehealth

Digital healthcare companies operate within a highly regulated environment.

Eucalyptus attracted attention regarding telehealth prescribing practices, particularly around GLP-1 medications used for weight management.

In 2023, the Royal Australian College of General Practitioners raised concerns about prescribing approaches involving remote questionnaires, while the Therapeutic Goods Administration issued guidance regarding Advertising prescription-only medicines to consumers.

During periods of medication shortages, Eucalyptus’s use of compounded semaglutide also attracted public discussion. Regulatory changes later affected pharmacy compounding practices involving GLP-1 medications.

These issues form part of broader discussions about balancing healthcare accessibility with clinical oversight. This article does not make claims about the safety or effectiveness of treatments, which depend on medical evidence and regulatory assessment.

The balance between access and oversight

Digital healthcare platforms are often developed around improving convenience and access.

Supporters argue that online healthcare services can provide additional Options for patients who face barriers such as location, time constraints or difficulty accessing appointments.

At the same time, healthcare professionals and regulators consider questions around clinical assessment, patient suitability and appropriate prescribing practices.

Eucalyptus’s development reflects these wider discussions about how healthcare services can be delivered through technology.

Building a healthcare technology company

Creating a digital healthcare company requires more than developing software.

Businesses in this sector must consider healthcare regulations, clinical processes, technology infrastructure and relationships with healthcare professionals.

Eucalyptus’s model involved combining technology with healthcare services across multiple specialised brands.

The company has stated that it achieved healthcare accreditation through the Australian Council on Healthcare Standards, which it has referenced in discussions around quality and safety processes.

Understanding founder Wealth estimates

As Eucalyptus was privately held before its acquisition, estimates of Tim Doyle’s wealth are based on external assessments of ownership interests and transaction value.

These estimates do not represent publicly disclosed cash holdings and can change depending on business valuations and transaction details.

The Eucalyptus business journey

Tim Doyle’s journey with Eucalyptus demonstrates the opportunities and challenges involved in digital healthcare.

The company developed around the idea that technology could support healthcare access through online services, while also operating within a sector where regulation and clinical standards are important considerations.

The broader lesson from Eucalyptus is that healthcare technology businesses must balance innovation, accessibility and responsibility as they scale.